Today: 18 April 2026
Subscribe
Browse Category

NASDAQ:DFNT 18 April 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
18 April 2026
··

Stock Market Today

  • Jim Cramer Endorses Madison Air (MAIR) as Buy After Strong IPO Debut
    April 18, 2026, 3:25 PM EDT. Madison Air Solutions Corporation (NYSE:MAIR) caught Jim Cramer's attention in his latest stock picks. Following its recent IPO, Cramer described MAIR as a "successful rollup" in the airflow and cooling sector with solid revenue growth and profitability. He highlighted the company's competitive valuation and likened it to industry peers like Vertiv and Trane, suggesting the stock is attractively priced at around $32 per share. Cramer set an initial price target of $41, indicating confidence despite the stock's strong market debut. The reopening IPO market and Madison Air's strategic acquisitions underpin his positive outlook. MAIR manufactures HVAC and air quality systems, with brands such as Reznor and Big Ass Fans, also offering design and repair services.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Go toTop